SUGAMMADEX versus neostigmine after ROCURONIUM continuous infusion in patients undergoing liver transplantation

Cristian Deana, Federico Barbariol, Stefano D'Incà, Livia Pompei, Giorgio Della Rocca, Cristian Deana, Federico Barbariol, Stefano D'Incà, Livia Pompei, Giorgio Della Rocca

Abstract

Background: Rapid neuromuscular block reversal at the end of major abdominal surgery is recommended to avoid any postoperative residual block. To date, no study has evaluated sugammadex performance after rocuronium administration in patients undergoing liver transplantation. This is a randomized controlled trial with the primary objective of assessing the neuromuscular transmission recovery time obtained with sugammadex versus neostigmine after rocuronium induced neuromuscular blockade in patients undergoing orthotopic liver transplantation.

Methods: The TOF-Watch SX®, calibrated and linked to a portable computer equipped with TOF-Watch SX Monitor Software®, was used to monitor and record intraoperative neuromuscular block maintained with a continuous infusion of rocuronium. Anaesthetic management was standardized as per our institution's internal protocol. At the end of surgery, neuromuscular moderate block reversal was obtained by administration of 2 mg/kg of sugammadex or 50 mcg/kg of neostigmine (plus 10 mcg/kg of atropine).

Results: Data from 41 patients undergoing liver transplantation were analysed. In this population, recovery from neuromuscular block was faster following sugammadex administration than neostigmine administration, with mean times±SD of 9.4 ± 4.6 min and 34.6 ± 24.9 min, respectively (p < 0.0001).

Conclusion: Sugammadex is able to reverse neuromuscular block maintained by rocuronium continuous infusion in patients undergoing liver transplantation. The mean reversal time obtained with sugammadex was significantly faster than that for neostigmine. It is important to note that the sugammadex recovery time in this population was found to be considerably longer than in other surgical settings, and should be considered in clinical practice.

Trial registration: ClinicalTrials.govNCT02697929 (registered 3rd March 2016).

Keywords: Liver transplantation; Neostigmine; Recovery time; Reversal; Rocuronium.

Conflict of interest statement

Nothing to declare.

Figures

Fig. 1
Fig. 1
Study flow-chart according to CONSORT. LTx, orthotopic liver transplantation; GFR, glomerular filtration rate
Fig. 2
Fig. 2
Recovery time for sugammadex and neostigmine. Mean value was 9.4 vs. 34.6 minutes for sugammadex and neostigmine respectively (p < 0.0001)

References

    1. Madsen MV, Scheppan S, Mørk E, Kissmeyer P, Rosenberg J, Gätke MR. Influence of deep neuromuscular block on the surgeonś assessment of surgical conditions during laparotomy: a randomized controlled double blinded trial with rocuronium and sugammadex. Br J Anaesth. 2017;119:435–442.
    1. Bruintjes MH, van Helden EV, Braat AE, et al. Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis. Br J Anaesth. 2017;118:834–842.
    1. Fernando PU, Viby-Mogensen J, Bonsu AK, Tamilarasan A, Muchhal KK, Lambourne A. Relationship between posttetanic count and response to carinal stimulation during vecuronium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1987;31:593–596.
    1. Dhonneur G, Kirov K, Motamed C, et al. Post-tetanic count at adductor pollicis is a better indicator of early diaphragmatic recovery than train-of-four count at corrugator supercilii. Br J Anaesth. 2007;99:376–379.
    1. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia. 2007;62:12–17.
    1. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, Krintel JJ. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anesthesiol Scand. 1997;41:1095–1103.
    1. Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology. 2008;109:389–398.
    1. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000;92:977–984.
    1. Arbous MS, Meursing AE, van Kleef JW, et al. Impact of anesthesia management characterics on severe morbidity and mortality. Anesthesiology. 2005;102:257–268.
    1. Kotake Y, Ochiai R, Suzuki Tet al. Reversal with Sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117:345–351.
    1. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41:1095–1103.
    1. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting nondepolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329.
    1. Italian Society of Anesthesia and Intensive Care. Guidelines. .
    1. Van Miert MM, Eastwood NB, Boyd AH, Parker CJ, Hunter JM. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol. 1997;44:139–144.
    1. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010;27:874–881.
    1. Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012;67:991–998.
    1. Biancofiore G, Tomescu DR, Mandell MS. Rapid recovery of liver transplantation recipients by implementation of fast-track care steps: what is holding us Back? Semin Cardiothorac Vasc Anesth. 2018;22:191–196.
    1. Perilli V, Aceto P, Sacco T, et al. Anaesthesiological strategies to improve outcome in liver transplantation recipients. Eur Rev Med Pharmacol Sci. 2016;20:3172–3177.
    1. Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia. 2009;64:55–65.
    1. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;11:120–128.
    1. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109:816–824.
    1. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569–574.
    1. Della Rocca G, Pompei L, Pagan De Paganis C, et al. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study. Acta Anesthesiol Scand. 2013;57:1138–1145.
    1. Fujita A, Ishibe N, Yoshihara T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. Acta Anaesthesiol Taiwanica. 2014;52:54–58.
    1. Abdulatif M, Lotfy M, Mousa M, Afifi MH, Yassen K. Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. Minerva Anestesiol. 2018;84(8):929–937.
    1. Illman HL, Laurila P, Antila H, Meretoja OA, Alahuhta S, Olkkola KT. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. Anesth Analg. 2011;112:63–68.
    1. Llaurado S, Sabate A, Ferreres E, Camprubí I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012;117:93–98.
    1. Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investing. 2011;31:101–111.
    1. Rezonja K, Sostaric M, Vidmar G, Mars T. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells. Anesth Analg. 2014;118(4):755–763.
    1. Rezonja K, Mars T, Jerin A, Kozelj G, Pozar-Lukanovic N, Sostaric M. Examethasone does not diminish sugammadex reversal of neuromuscular block - clinical study in surgical patients undergoing general anesthesia. BMC Anesthesiol. 2016;16(1):101.
    1. Saleh RS, Moustafa MA. Recovery from rocuronium with sugammadex in children premedicated with dexamethasone for prevention of postoperative nausea and vomiting. Egyptian J Anaesthesia. 2017;33:1–4.
    1. Ozer AB, Bolat E, Erhan OL, Kilinc M, Demirel I, Toprak GC. Sugammadex improves neuromuscular function in patients receiving perioperative steroids. Niger J Clin Pract. 2018;21:139–142.
    1. Kandemir T, Kandemir E, Aşkın T, Muslu S, Tuncel GO, Ünver S. Effect of concurrent Lidocaine, Remifentanil and methylprednisolone use on the clinical effect of Sugammadex under general Anaesthesia in rats. Turk J Anaesthesiol Reanim. 2019;47(5):392–395.
    1. Zhang L, Yang L, Bi SS, Lu W, Zhang X-H, Zhai S-D, Duan L-P. Population pharmacokinetics of Remifentanil in patients undergoing Orthotopic liver transplantation. Chin Med J. 2009;122(9):1032–1038.
    1. Gao L, Ramzan I, Baker B. Rocuronium infusion requirements and plasma concentrations at constant levels of neuromuscular paralysis during three phases of liver transplantation. J Clin Anesth. 2003;15:257–266.
    1. Gao L, Ramzan I, Baker B. Rocuronium plasma concentrations during three phases of liver transplantation: relationship with early postoperative graft liver function. BJA. 2002;88:764–770.
    1. Marcel RJ, Ramsay MA, Hein HA, et al. Duration of Rocuronium-induced neuromuscular block during liver transplantation: a predictor of primary allograft function. Anesth Analg. 1997;84:870–874.
    1. Cammu G, Bossuyt G, De Baerdemaeker L, Den Blauwen N, Struys M, Mortier E. Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation. J Clin Anesth. 2002;14:135–139.
    1. Bhangui P, Bhangui P, Gupta N, Jolly AS, Bhalotra S, Sharma N, et al. Fast tracking in adult living donor liver transplantation: a case series of 15 patients. Indian J Anaesth. 2018;62:127–130.
    1. A.P., Ragonete dos Anjos Agostini, I. de Fatima Santana Boin R. Martins Tonella A.M., Heidemann dos Santos A.L., Eiras Falcão C., Muterli Logato L., dos Santos Roceto Ratti L., Castilho de Figueiredo, L.C. Martins. Mortality Predictors After Liver Transplant in the Intensive Care Unit. Transplant Proc. 2018;50:1424–427.
    1. De Kam P-J, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, Langdon RB, Peeters P. Effects of Sugammadex on activated partial Thromboplastin time and Prothrombin time in healthy subjects. Int J Clin Pharmacol Ther. 2014;52(3):227–236.
    1. Iwasaki H, Renew JR, Kunisawa T, Brull SJ. Preparing for the unexpected: special considerations and complications after Sugammadex administration. BMC Anesthesiol. 2017;17:140.
    1. Dirkmann D, Britten MW, Pauling H, Weidle J, Volbracht L, Görlinger K, Peters J. Anticoagulant effect of Sugammadex: just an In Vitro artifact. Anesthesiology. 2016;124:1277–1285.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel